Drug Profile
Anthrax vaccine - Aparna Biosciences
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Aparna Biosciences
- Class Anthrax vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Anthrax
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Anthrax in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Anthrax in USA
- 21 Jul 2016 Anthrax vaccine - Aparna Biosciences is available for licensing as of 21 Jul 2016. http://www.aparnabio.com/